Besides ibrutinib, people with M-CLL, devoid of TP53 aberrations and fit more than enough to tolerate FCR therapy, may still be great candidates for the latter, Using the benefit being that this cure is often completed in 6 months even though ibrutinib has to be taken indefinitely. This feature could be significantly worthwhile for non-compliant in